ONTX Onconova Therapeutics, Inc.

-0.01  -0%
Previous Close 2.09
Open 2.11
Price To book 0.00
Market Cap 19.73M
Shares 9,487,000
Volume 18,401
Short Ratio 4.01
Av. Daily Volume 193,900

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned. Protocol for proposed trial to be submitted to FDA 3Q 2017.
Oral Rigosertib and azacitidine 09-08 trial
Myelodysplastic Syndromes (MDS) and Acute myeloid leukemia (AML) cancer
Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid
  2. Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
  3. Onconova Therapeutics to Present at the BIO International Convention
  4. UPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results
  5. Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting
  6. Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association
  7. Edited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT
  8. Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting
  9. Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results
  10. Investor Network: Onconova Therapeutics Inc. to Host Earnings Call
  11. Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results
  12. Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes
  13. Onconova Therapeutics Announces Closing of Public Offering of Common Stock
  14. Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC
  15. Onconova Therapeutics stock drops 12% after pricing stock offering
  16. Onconova Therapeutics Announces Pricing of Public Offering of Common Stock
  17. Onconova Therapeutics Announces Proposed Public Offering of Common Stock
  18. Company News for April 05, 2017
  19. Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval

SEC Filings

  1. 8-K - Current report 17870952
  2. 8-K - Current report 17854521
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17845169
  4. 8-K - Current report 17841359
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 17799454
  6. 8-K - Current report 17778571
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17778547
  8. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 17774010
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17773720
  10. 8-K - Current report 17773711